SIGNANT HEALTH
THE EVIDENCE GENERATION COMPANY™

Prostate Cancer Clinical Trial Solutions

MAKING STRIDES TOWARD NEW TREATMENTS

ONE STUDY AT A TIME

Prostate cancer is the most common cancer among men, but it can be treated successfully. Signant Health applies decades of clinical experience in oncology studies and deep therapeutic expertise with prostate cancer to facilitate the approval of new therapies and treatments. Coupled with clinical trial technology solutions in our SmartSignals suite, we optimize the quality and reliability of clinical data, helping study teams identify new therapies sooner.

OPTIMIZE PROM RELIABILITY & EXPEDITE STUDY START-UP

Key endpoints in prostate cancer trials require reliable patient reported outcomes measurement (PROM) data. Signant's pre-configured eCOA solution for oncology provides electronic, pre-validated prostate cancer instruments that help patients provide complete, accurate, and timely responses, improving PRO accuracy compared to paper and pencil.

In addition, launching studies faster can help expand the reach and impact of potential therapies and treatments. Signant's pre-configured eCOA solution enables *33% faster study start-up at 20% less cost.*

PREVENT WASTE AND REDUCE SHIPMENTS & RETURNS

Prostate cancer studies often involve multiple patient cohorts and complex dosing schedules. Another variable adding complexity, investigational products for prostate cancer studies can be expensive as well as limited in supply and shelf life.

Signant's RTSM system utilizes unique algorithms to implement complex randomization schemes rapidly as well as optimize lot usage and efficiency. We support your study with a project team of multidisciplinary clinical science and operations experts from launch to closeout.

INCREASE PATIENT COMPREHENSION & EASE BURDENS FOR SITES & PATIENTS

Oncology studies are complex and treatments carry risks that should be understood by well-informed patients. Signant's eConsent solution improves comprehension and patient experience while providing sites with important version control features that ensure up-to-date informed consent forms.

COLLECT MORE COMPLETE PATIENT FUNCTION DATA

Help your study team collect accurate data about treatment effects on patient function. We integrate ActiGraph with our eCOA system to automatically collect sleep and activity data without additional burden on patients or sites. Study teams can view this data alongside COA data for a more complete evaluation of patient function.

DIGITIZE STUDIES FOR END-TO-END ACCURACY & VISIBILITY

While all of our solutions can be used as standalone tools, when combined they enhance the accuracy and efficiency of your prostate cancer study. Gain immediate access to electronic data for faster decision-making and improved regulatory inspections.

Signant's end-to-end suite of evidence generation solutions and accompanying prostate cancer clinical science and medicine expertise reduce burdens for participants and study teams while generating more accurate, reliable data to improve confidence in study outcome conclusions.

SIGNANT'S PROSTATE CANCER CLINICAL TRIAL SOLUTIONS EXPERIENCE IN THE PAST 5 YEARS

Phases

I II III IV



46 Languages

7,400 Sites

42 Countries

29,000 Patients

96 Trials

INSTRUMENTS

FACT-P | EORTC-QLQ-PR25 | EQ-5D-5L | EORTC-QLQ-C30

SMARTSIGNALS SOLUTIONS

The solutions can be used individually or integrated together for a seamless, end-to-end digital experience.

eCOA

RTSM

Telemedicine

eConsent



DISCUSS YOUR NEXT PROSTATE CANCER STUDY WITH US

Our global team of therapeutic area experts advise on all areas of the clinical development process, including:

- Clinical science and medicine
- Data analysis
- Regulatory
- Operations and trial administration
- Global logistics

MEET THE EXPERTS